CURA_1170x120_8-22-19

Peter Goldschmidt

Sandoz releases Pataday authorized generic

Sandoz releases Pataday authorized generic

PRINCETON, N.J. — Sandoz Inc. has launched olopatadine hydrochloride ophthalmic solution 0.2%, an antihistamine for itchy eyes, in the United States. Sandoz said the product is an authorized generic version of Pataday eye drops from Alcon. Both Sandoz and Alcon are subsidiaries of Novartis. A mast cell stabilizer, olopatadine hydrochloride ophthalmic solution 0.2% is indicated

New name for Generic Pharmaceutical Association

New name for Generic Pharmaceutical Association

WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly

Sandoz releases generic version of Latisse

Sandoz releases generic version of Latisse

PRINCETON, N.J. — Sandoz Inc. has introduced bimatoprost ophthalmic solution 0.03%, an eyelash treatment, in the U.S. market. The Novartis subsidiary said its bimatoprost ophthalmic product is a generic version of Latisse from Allergan. A prescription medicine, bimatoprost ophthalmic solution 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length,

Sandoz releases generic Crestor in U.S. market

Sandoz releases generic Crestor in U.S. market

PRINCETON, N.J. — Sandoz has launched rosuvastatin calcium tablets, a cholesterol-lowering medication, in the United States. The Novartis division said Thursday that its rosuvastatin calcium product, a generic version of Crestor from AstraZeneca Pharmaceuticals, will be marketed in dosages of 5 mg, 10 mg, 20 mg and 40 mg. U.S. sales for Crestor totaled approximately

Sandoz releases generic of Exelon patch in U.S.

Sandoz releases generic of Exelon patch in U.S.

PRINCETON, N.J. — Sandoz has launched a rivastigmine patch, a treatment for dementia, in the U.S. market. The Novartis subsidiary said Wednesday that its rivastigmine transdermal system is an authorized generic version of the Exelon patch, marketed by Novartis Pharmaceuticals Corp. Sandoz is marketing its rivastigmine patch in 13.3-mg strength, the same strength as the

Sandoz releases Pulmicort Respules generic

PRINCETON, N.J. — Sandoz has launched budesonide inhalation suspension, an asthma medication, in the U.S. market. The Novartis subsidiary said Tuesday that it will market its budesonide inhalation suspension in 1-mg strength, and it expects 180-day generic drug marketing exclusivity for that dosage. The product is a a generic version of Pulmicort Respules inhalation suspension

Sandoz cleared to market Copaxone generic

HOLZKIRCHEN, Germany — Sandoz has received Food and Drug Administration approval for Glatopa, a treatment for multiple sclerosis (MS). The Novartis subsidiary said Thursday that its product is the first generic version of Teva’s Copaxone (glatiramer acetate injection) 20 mg/ml once-daily MS therapy. Glatopa, developed in collaboration with Momenta and made entirely in the United

Sandoz launches Exforge generic

PRINCETON, N.J. — Sandoz Inc. has released amlodipine and valsartan combination tablets, a hypertension medication, in the United States. The company said Tuesday that its product is a generic version of Exforge, made by Novartis. Sandoz will market its combination amlodipine/valsartan tablets in strengths of 5-160 mg, 5-320 mg, 10-160 mg, 10-320 mg, the same